Enliven Therapeutics Overview
Enliven Therapeutics Target Price
Analysts' average 12-month price target for Enliven Therapeutics is $73.
Get informed when a big investor buys or sells
+ FollowShare Price
$45.84
Average Target Price
$72.50
58.2% upside
58.2% upside10 analysts in the last 4 months
High: $82 | Low: $60
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-08-18 | Mizuho SecuritiesSalim Syed | $73 | 59.2% upside |  |
| 2026-08-18 | BarclaysEtzer Darout | $78 | 70.2% upside | |
| 2026-08-06 | Stifel NicolausDara Azar | $82 | 78.9% upside | |
| 2026-08-06 | GuggenheimMichael Schmidt | $78 | 70.2% upside | |
| 2026-08-06 | Goldman Sachs | $80 | 74.5% upside | |
| 2026-07-21 | Goldman SachsSalveen Richter | $67 | 46.2% upside | |
| 2026-07-09 | H.C. WainwrightRobert Burns | $65 | 41.8% upside | |
| 2026-07-01 | Stifel Nicolaus | $80 | 74.5% upside | |
| 2026-06-08 | Stifel Nicolaus | $60 | 30.9% upside | |
| 2026-06-02 | Mizuho SecuritiesSalim Syed | $62 | 35.3% upside | |
| 2026-05-12 | Guggenheim | $80 | 74.5% upside | |
| 2026-05-08 | Goldman Sachs | $59 | 28.7% upside | |
| 2025-06-16 | Robert W. BairdColleen Kusy | $52 | 13.4% upside | |
| 2025-03-21 | H.C. Wainwright | $39 |  14.9% downside | |
| 2024-11-15 | Robert W. BairdColleen Kusy | $40 | 12.7% downside | |
| 2024-09-23 | Mizuho SecuritiesSalim Syed | $39 | 14.9% downside | |
| 2024-06-10 | Robert W. BairdColleen Kusy | $32 | 30.2% downside | |
| 2024-04-09 | Mizuho SecuritiesSalim Syed | $34 | 25.8% downside | |